Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003139 · ClinicalTrials.gov registry record · Phase 3
Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer
A Phase 3 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 249
- Enrollment target
NCT00003139 is a Phase 3 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 249 participants.
The verdict
NCT00003139, a Phase 3 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 249 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as pilocarpine may protect normal cells from the side effects of radiation therapy. It is not yet known if pilocarpine may be effective in preventing mucositis and dry mouth in patients receiving radiation therapy for head and neck cancer. PURPOSE: Randomized, double-blinded, phase III trial to study the effectiveness of pilocarpine in preventing mucositis and dry mouth in patients receiving radiation therapy for head and neck cancer.
Interventions
- OTHER Placebo
- DRUG pilocarpine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 249 participants |
| Start Date | 1998-03 |
| Est. Completion | 2002-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003139
The ClinicalTrials.gov registry entry for NCT00003139 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 249 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00003139 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003139 about?
NCT00003139 is a clinical study titled "Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as pilocarpine may protect normal cells from the side effects of radiation therapy. It is not yet known if pilocarpine may be effective in preventing mucositis and dry mouth in patients receiving radiation therapy...
What is the current status of trial NCT00003139?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 249 participants. The study started on 1998-03. Estimated completion is 2002-10.
What interventions are being tested in trial NCT00003139?
The interventions under investigation include: Placebo (OTHER), pilocarpine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003139?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.